Literature DB >> 27193225

Composition of Rosenthal Fibers, the Protein Aggregate Hallmark of Alexander Disease.

Michael R Heaven, Daniel Flint, Shan M Randall1, Alexander A Sosunov, Landon Wilson, Stephen Barnes, James E Goldman, David C Muddiman1, Michael Brenner.   

Abstract

Alexander disease (AxD) is a neurodegenerative disorder characterized by astrocytic protein aggregates called Rosenthal fibers (RFs). We used mouse models of AxD to determine the protein composition of RFs to obtain information about disease mechanisms including the hypothesis that sequestration of proteins in RFs contributes to disease. A method was developed for RF enrichment, and analysis of the resulting fraction using isobaric tags for relative and absolute quantitation mass spectrometry identified 77 proteins not previously associated with RFs. Three of five proteins selected for follow-up were confirmed enriched in the RF fraction by immunobloting of both the AxD mouse models and human patients: receptor for activated protein C kinase 1 (RACK1), G1/S-specific cyclin D2, and ATP-dependent RNA helicase DDX3X. Immunohistochemistry validated cyclin D2 as a new RF component, but results for RACK1 and DDX3X were equivocal. None of these was decreased in the non-RF fractions compared to controls. A similar result was obtained for the previously known RF component, alphaB-crystallin, which had been a candidate for sequestration. Thus, no support was obtained for the sequestration hypothesis for AxD. Providing possible insight into disease progression, the association of several of the RF proteins with stress granules suggests a role for stress granules in the origin of RFs.

Entities:  

Keywords:  Alexander disease; Rosenthal fiber; astrocyte; mass spectrometry (MS); neurodegenerative disease; protein aggregates; proteomics; stress granules

Mesh:

Substances:

Year:  2016        PMID: 27193225      PMCID: PMC5036859          DOI: 10.1021/acs.jproteome.6b00316

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  66 in total

1.  RACK1 binds to inositol 1,4,5-trisphosphate receptors and mediates Ca2+ release.

Authors:  Randen L Patterson; Damian B van Rossum; Roxanne K Barrow; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

2.  Highly reproducible label free quantitative proteomic analysis of RNA polymerase complexes.

Authors:  Amber L Mosley; Mihaela E Sardiu; Samantha G Pattenden; Jerry L Workman; Laurence Florens; Michael P Washburn
Journal:  Mol Cell Proteomics       Date:  2010-11-03       Impact factor: 5.911

3.  Spectral counting robust on high mass accuracy mass spectrometers.

Authors:  Wolfgang Hoehenwarter; Stefanie Wienkoop
Journal:  Rapid Commun Mass Spectrom       Date:  2010-12-30       Impact factor: 2.419

4.  Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease.

Authors:  Guomei Tang; Zhiheng Xu; James E Goldman
Journal:  J Biol Chem       Date:  2006-10-10       Impact factor: 5.157

5.  Prominent white matter cavitation in an infant with Alexander's disease.

Authors:  E A Klein; A P Anzil
Journal:  Clin Neuropathol       Date:  1994 Jan-Feb       Impact factor: 1.368

Review 6.  GFAP mutations in Alexander disease.

Authors:  Rong Li; Albee Messing; James E Goldman; Michael Brenner
Journal:  Int J Dev Neurosci       Date:  2002 Jun-Aug       Impact factor: 2.457

7.  Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization.

Authors:  Ye V Liu; Maimon E Hubbi; Fan Pan; Karin R McDonald; Malini Mansharamani; Robert N Cole; Jun O Liu; Gregg L Semenza
Journal:  J Biol Chem       Date:  2007-10-26       Impact factor: 5.157

8.  GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Authors:  M Prust; J Wang; H Morizono; A Messing; M Brenner; E Gordon; T Hartka; A Sokohl; R Schiffmann; H Gordish-Dressman; R Albin; H Amartino; K Brockman; A Dinopoulos; M T Dotti; D Fain; R Fernandez; J Ferreira; J Fleming; D Gill; M Griebel; H Heilstedt; P Kaplan; D Lewis; M Nakagawa; R Pedersen; A Reddy; Y Sawaishi; M Schneider; E Sherr; Y Takiyama; K Wakabayashi; J R Gorospe; A Vanderver
Journal:  Neurology       Date:  2011-09-14       Impact factor: 11.800

9.  Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models.

Authors:  Hyung-Jun Kim; Alya R Raphael; Eva S LaDow; Leeanne McGurk; Ross A Weber; John Q Trojanowski; Virginia M-Y Lee; Steven Finkbeiner; Aaron D Gitler; Nancy M Bonini
Journal:  Nat Genet       Date:  2013-12-15       Impact factor: 38.330

10.  De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome.

Authors:  Ghayda Mirzaa; David A Parry; Andrew E Fry; Kristin A Giamanco; Jeremy Schwartzentruber; Megan Vanstone; Clare V Logan; Nicola Roberts; Colin A Johnson; Shawn Singh; Stanislav S Kholmanskikh; Carissa Adams; Rebecca D Hodge; Robert F Hevner; David T Bonthron; Kees P J Braun; Laurence Faivre; Jean-Baptiste Rivière; Judith St-Onge; Karen W Gripp; Grazia Ms Mancini; Ki Pang; Elizabeth Sweeney; Hilde van Esch; Nienke Verbeek; Dagmar Wieczorek; Michelle Steinraths; Jacek Majewski; Kym M Boycot; Daniela T Pilz; M Elizabeth Ross; William B Dobyns; Eamonn G Sheridan
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

View more
  19 in total

1.  Relative stabilities of wild-type and mutant glial fibrillary acidic protein in patients with Alexander disease.

Authors:  Michael R Heaven; Landon Wilson; Stephen Barnes; Michael Brenner
Journal:  J Biol Chem       Date:  2019-09-04       Impact factor: 5.157

2.  Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.

Authors:  Tracy L Hagemann; Berit Powers; Curt Mazur; Aneeza Kim; Steven Wheeler; Gene Hung; Eric Swayze; Albee Messing
Journal:  Ann Neurol       Date:  2018-01-14       Impact factor: 10.422

Review 3.  The multifaceted nature of αB-crystallin.

Authors:  Junna Hayashi; John A Carver
Journal:  Cell Stress Chaperones       Date:  2020-05-07       Impact factor: 3.667

4.  Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.

Authors:  Laura R Moody; Gregory A Barrett-Wilt; Michael R Sussman; Albee Messing
Journal:  J Biol Chem       Date:  2017-02-21       Impact factor: 5.157

Review 5.  Alexander disease: models, mechanisms, and medicine.

Authors:  Tracy L Hagemann
Journal:  Curr Opin Neurobiol       Date:  2021-11-23       Impact factor: 6.627

6.  Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment.

Authors:  Tracy L Hagemann; Berit Powers; Ni-Hsuan Lin; Ahmed F Mohamed; Katerina L Dague; Seth C Hannah; Gemma Bachmann; Curt Mazur; Frank Rigo; Abby L Olsen; Mel B Feany; Ming-Der Perng; Robert F Berman; Albee Messing
Journal:  Sci Transl Med       Date:  2021-11-17       Impact factor: 17.956

Review 7.  Characterization of gliomas: from morphology to molecules.

Authors:  Sean P Ferris; Jeffrey W Hofmann; David A Solomon; Arie Perry
Journal:  Virchows Arch       Date:  2017-07-04       Impact factor: 4.064

Review 8.  Heterogeneity of white matter astrocytes in the human brain.

Authors:  Marianna Bugiani; Bonnie C Plug; Jodie H K Man; Marjolein Breur; Marjo S van der Knaap
Journal:  Acta Neuropathol       Date:  2021-12-08       Impact factor: 17.088

9.  Two Metabolic Fuels, Glucose and Lactate, Differentially Modulate Exocytotic Glutamate Release from Cultured Astrocytes.

Authors:  Vedrana Montana; Daniel Flint; Helle S Waagepetersen; Arne Schousboe; Vladimir Parpura
Journal:  Neurochem Res       Date:  2021-05-31       Impact factor: 4.414

10.  Anastasis Drives Senescence and Non-Cell Autonomous Neurodegeneration in the Astrogliopathy Alexander Disease.

Authors:  Liqun Wang; Hassan Bukhari; Linghai Kong; Tracy L Hagemann; Su-Chun Zhang; Albee Messing; Mel B Feany
Journal:  J Neurosci       Date:  2022-02-01       Impact factor: 6.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.